Gupta Tejpal, Kalra Babusha, Goswami Savita, Deodhar Jayita, Rane Pallavi, Epari Sridhar, Moiyadi Aliasgar, Dasgupta Archya, Chatterjee Abhishek, Chinnaswamy Girish
Department of Radiation Oncology, Advanced Centre for Treatment Research & Education in Cancer (ACTREC)/Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Parel, Mumbai, India.
Clinical Psychology & Psychiatry Unit, Advanced Centre for Treatment Research & Education in Cancer (ACTREC)/Tata Memorial Hospital (TMH), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Parel, Mumbai, India.
Neurooncol Pract. 2022 Mar 13;9(3):236-245. doi: 10.1093/nop/npac020. eCollection 2022 May.
The purpose of this study was to report long-term neurocognitive and clinical outcomes in children treated for average-risk medulloblastoma with hyperfractionated radiation therapy (HFRT) alone.
Between 2006 and 2010, 20 children with rigorously staged average-risk medulloblastoma were treated on a prospective study with HFRT without upfront adjuvant systemic chemotherapy after written informed consent. HFRT was delivered as twice-daily fractions (1 Gy/fraction, 6-8 hours apart, 5 days/week) to craniospinal axis (36 Gy/36 fractions) plus conformal tumor-bed boost (32 Gy/32 fractions). Neurocognitive function was assessed at baseline and periodically on follow-up using age-appropriate intelligence quotient (IQ) scales.
Median age was 8 years (range 5-14 years) with 70% being males. Mean and standard deviation (SD) scores at baseline were 90.5 (SD = 17.08), 88 (SD = 16.82) and 88 (SD = 17.24) for Verbal Quotient (VQ), Performance Quotient (PQ), and Full-Scale IQ (FSIQ) respectively. Mean scores remained stable in the short-to-medium term but declined gradually beyond 5 years with borderline statistical significance for VQ ( = .042), but nonsignificant decline in PQ ( = .259) and FSIQ ( = .108). Average rate of neurocognitive decline was <1 IQ point per year over a 10-year period. Regression analysis stratified by age, gender, and baseline FSIQ failed to demonstrate any significant impact of the tested covariates on longitudinal neurocognitive function. At a median follow-up of 145 months, 10-year Kaplan-Meier estimates of progression-free survival and overall survival were 63.2% and 74.1% respectively.
HFRT alone without upfront adjuvant chemotherapy in children with average-risk medulloblastoma is associated with modest decline in neurocognitive functioning with acceptable long-term survival outcomes and may be most appropriate for resource-constrained settings.
本研究的目的是报告仅接受超分割放射治疗(HFRT)的平均风险髓母细胞瘤患儿的长期神经认知和临床结局。
2006年至2010年间,20例严格分期的平均风险髓母细胞瘤患儿在获得书面知情同意后,参加了一项前瞻性研究,接受HFRT治疗,未进行前期辅助全身化疗。HFRT采用每日两次分割照射(每次1 Gy,间隔6 - 8小时,每周5天),照射颅脊髓轴(36 Gy / 36次分割)加适形肿瘤床推量照射(32 Gy / 32次分割)。在基线时以及随访期间定期使用适合年龄的智商(IQ)量表评估神经认知功能。
中位年龄为8岁(范围5 - 14岁),70%为男性。言语智商(VQ)、操作智商(PQ)和全量表智商(FSIQ)在基线时的平均得分及标准差分别为90.5(SD = 17.08)、88(SD = 16.82)和88(SD = 17.24)。平均得分在短期至中期保持稳定,但在5年后逐渐下降,VQ有临界统计学意义(P = .042),PQ(P = .259)和FSIQ(P = .108)无显著下降。在10年期间,神经认知下降的平均速率<每年1个IQ点。按年龄、性别和基线FSIQ分层的回归分析未能显示所测试的协变量对纵向神经认知功能有任何显著影响。在中位随访145个月时,10年无进展生存率和总生存率的Kaplan - Meier估计分别为63.2%和74.1%。
对于平均风险髓母细胞瘤患儿,仅接受HFRT而不进行前期辅助化疗会导致神经认知功能有适度下降,但长期生存结局可接受,可能最适合资源有限的环境。